Consensus Discussion and Conclusions

  • J. Ginsburg
Conference paper


A consensus view of the role of Sandostatin® in acromegaly and the indications for its use were formulated after discussion of the various papers and posters presented at the meeting. For this purpose the participants separated into three working parties which reviewed Sandostatin therapy in (I) newly diagnosed and previously untreated acromegalic patients, in (II) treatment of the perioperative period before pituitary surgery or in (III) previously treated acromegalic patients where surgery and/or radiotherapy had failed to control activity of the acromegalic process. The reports of the working parties were then presented at a gathering of all participants and recommendations made to guide those using the drug for the first time. The ensuing discussion also highlighted the many aspects requiring further assessment and the difficulty of conducting a “conventional” drug trial in patients with acromegaly.


Growth Hormone Carpal Tunnel Syndrome Growth Hormone Secretion Growth Hormone Level Acromegalic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of Acromegaly in the Newcastle Region. Clin Endocrinol 12: 71–79CrossRefGoogle Scholar
  2. 2.
    Klijn JGM, Lamberts SWJ, de Jong FH, van Dongen KJ, Birkenhäger JC (1980) Interrelationships between tumour size, age,Consensus Discussion and Conclusionsplasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinol 95: 289–297Google Scholar
  3. 3.
    Lamberts SWJ, Oosterom R, Neufeld M, Del Pozo E (1985) The somatostatin analog SMS 201–995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60: 1161–1165.CrossRefPubMedGoogle Scholar
  4. 4.
    Lamberts SWJ, Uitterlinden P, Del Pozo E (1987) Sandostatin (SMS 201–995) induces a continuous further decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab 65: 703–710CrossRefPubMedGoogle Scholar
  5. 5.
    Lamberts SWJ, Uitterlinden P, Verleun T (1987) The relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with Sandostatin (SMS 201–995). Eur J Clin Invest 17: 354–359CrossRefPubMedGoogle Scholar
  6. 6.
    Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, Del Pozo E (1985) Longterm treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 313: 1576–1580CrossRefPubMedGoogle Scholar
  7. 7.
    Lamberts SWJ, Verleun T, Hofland LJ, Del Pozo E (1987) A comparison between the effects of Sandostatin (SMS 201–995), bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients. Clin Endocrinol (Oxf) 27: 11–23CrossRefGoogle Scholar
  8. 8.
    Lamberts SWJ, Zweens M, Klijn JGM, van Vroonhoven CCJ, Stefanko SZ, Del Pozo E (1986) The sensitivity of growth hormone and prolactin secretion of the somatostatin analogue SMS 201–995 in patients with prolactinomas and acromegaly. Clin Endocrinol (Oxf) 25: 201–212CrossRefGoogle Scholar
  9. 9.
    Lamberts SWJ, Zweens M, Verschoor L, Del Pozo E (1986) A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab 63: 16–19CrossRefPubMedGoogle Scholar
  10. 10.
    Landolt AM, Keller PJ, Froesch ER, Müller J (1982) Bromocriptine: does it jeopardise the results of later surgery for prolactinomas? Lancet II: 657–658Google Scholar
  11. 11.
    Lindholm J, Giwercman B, Giwercman A, Astrup J, Bjerre P, Skakkebaek NE (1987) Investigation of the criteria for assessing the outcome of treatment in acromegaly. Clin Endocrinol (Oxf) 27: 553–562CrossRefGoogle Scholar
  12. 12.
    Pieters GFFM, Smals AGH, Kloppenborg PWC (1986) Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 314: 1391 (letter)Google Scholar
  13. 13.
    Plewe G, Schrezenmeir J, Nölken G, Krusse U, Beyer J, Kasper H, Del Pozo E (1986) Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995 over 6 months. Klin Wochenschr 64: 389–392CrossRefPubMedGoogle Scholar
  14. 14.
    Reubi JC, Landolt AM (1984) High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol 59: 1148–1153CrossRefGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1988

Authors and Affiliations

  • J. Ginsburg
    • 1
  1. 1.The Royal Free HospitalLondonUK

Personalised recommendations